Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Testing more genes upfront saves more lives. A new study in JNCCN found that advanced non-small cell lung cancer (NSCLC) patients who received broad-based genomic sequencing (BGS) before starting treatment lived about two months longer on average than those who had limited biomarker testing. The findings, drawn from over 35,000 real-world patients, reinforce NCCN Guidelines recommending comprehensive testing before first-line therapy.
Testing more genes upfront saves more lives in advanced lung cancer
A large real-world study published in the Journal of the National Comprehensive Cancer Network (JNCCN) confirms what guidelines have long recommended: comprehensive genomic testing before treatment for advanced non-small cell lung cancer (NSCLC) is associated with better survival outcomes. Analyzing data from over 35,000 patients treated across U.S. community and academic oncology practices between 2016 and 2022, researchers found that broad-based genomic sequencing (BGS) — testing dozens to hundreds of genes at once — was linked to a two-month improvement in overall survival compared to narrow, single-gene testing.
The reason? BGS identifies a wider range of actionable tumor biomarkers, enabling more patients to receive targeted therapies that are often more effective and better tolerated. Researchers and independent experts alike are calling for equitable access to BGS regardless of insurance status, provider, or geography.
By the Numbers
Why it matters: Comprehensive genomic testing is already guideline-recommended, but this study provides robust real-world evidence that it translates to longer lives — making the case for closing access gaps so all patients can benefit.
